Summary
Eli Lilly and Company (LLY) reported strong performance in its 2022 10-K filing, with total revenue reaching $28.54 billion, a slight increase from the previous year, driven by volume growth in key products like Trulicity, Verzenio, Jardiance, and Taltz. The company's profitability also saw a notable increase, with net income rising 12% to $6.24 billion. This growth was underpinned by robust clinical development progress, particularly in areas like diabetes with Mounjaro and cardiovascular disease. Despite facing patent expirations for some older products like Alimta, which led to significant revenue declines in those segments, Lilly demonstrated resilience through its strong pipeline and successful launches of newer, high-growth products. The company is heavily investing in research and development, with R&D expenses increasing to $7.19 billion, reflecting its commitment to innovation in therapeutic areas such as obesity, immunology, neuroscience, and oncology. Lilly is also strategically expanding its manufacturing capabilities to meet strong demand for its incretin products. While the company faces ongoing challenges from generic competition, pricing pressures, and evolving regulatory landscapes (including the Inflation Reduction Act), its strategic focus on innovation, pipeline development, and operational efficiency positions it for continued growth and value creation for shareholders.
Financial Highlights
53 data points| Revenue | $28.54B |
| Cost of Revenue | $6.63B |
| Gross Profit | $21.91B |
| R&D Expenses | $7.19B |
| SG&A Expenses | $6.44B |
| Interest Expense | $331.60M |
| Net Income | $6.24B |
| EPS (Basic) | $6.93 |
| EPS (Diluted) | $6.90 |
| Shares Outstanding (Basic) | 901.74M |
| Shares Outstanding (Diluted) | 904.62M |
Key Highlights
- 1Total revenue for 2022 was $28.54 billion, a 1% increase year-over-year, primarily driven by volume growth in key products.
- 2Net income increased by 12% to $6.24 billion, indicating improved profitability.
- 3Research and development expenses increased by 4% to $7.19 billion, reflecting significant investment in pipeline development.
- 4Key products like Trulicity, Verzenio, Jardiance, and Taltz showed strong revenue growth, contributing significantly to the top line.
- 5The launch of Mounjaro for type 2 diabetes shows promising uptake, with ongoing Phase II trials for obesity.
- 6The company is actively expanding manufacturing capacity to meet increasing demand for its incretin products.
- 7Revenue from Alimta significantly declined due to generic competition following patent expirations.